ACTINIUM PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
ACTINIUM PHARMACEUTICALS, INC. (ATNM) had Accumulated Other Comprehensive Income of -$60.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$60.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$39.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$20.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$60.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | -$39.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | -$20.00K 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |